TIBET PHARMA(SH:600211) Zheng Quan Zhi Xing·2025-08-15 16:14Core Viewpoint - Tibet Nordicon Pharmaceutical Co., Ltd. reported a slight increase in revenue but a decline in net profit for the first half of 2025, indicating potential challenges in profitability despite stable revenue growth [1]. Financial Performance - Total assets increased by 19.29% to CNY 5.66 billion compared to the end of the previous year [1]. - Net assets attributable to shareholders rose by 6.21% to CNY 4.16 billion [1]. - Revenue for the reporting period was CNY 1.65 billion, a 2.23% increase from CNY 1.61 billion in the same period last year [1]. - Total profit decreased by 8.41% to CNY 637.32 million from CNY 695.87 million year-on-year [1]. - Net profit attributable to shareholders fell by 8.96% to CNY 567.32 million compared to CNY 623.14 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses increased by 3.69% to CNY 542.84 million [1]. - Net cash flow from operating activities was CNY 600.22 million, a slight increase of 0.93% from CNY 594.71 million [1]. - The weighted average return on net assets decreased by 3.31 percentage points to 14.01% [1]. - Basic and diluted earnings per share were both CNY 1.76, down 8.81% from CNY 1.93 [1]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 45,191 [1]. - The top ten shareholders included Tibet Kangzhe Enterprise Management Co., Ltd. with a 32.28% stake and Tibet Huaxi Pharmaceutical Group Co., Ltd. with a 17.42% stake [2].